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ABSTRACT 
 
Globally, the microbe Neisseria gonorrhoeae (NG) causes 106 million newly 
documented sexually transmitted infections each year. Once appropriately 
diagnosed, NG infections can be treated with readily available antibiotics, but 
patients in low-resource settings often do not return to the clinic for results. As 
current NG diagnostic gold standards suffer from slow turnaround time to result, a 
rapid, sensitive molecular diagnostic would help increase appropriate treatment at 
the point-of-care. Here, we report on the design and development of a minimally-
instrumented paper-fluidic POC diagnostic that incorporates patient swab sample 
lysis, isothermal nucleic acid capture, thermophilic helicase-dependent 
amplification (tHDA), an internal amplification control (NGIC), and lateral flow 
visual detection. Limits of NG detection for the NG/NGIC multiplex tHDA assay 
were determined within the device, and device clinical performance was validated 
retroactively against qPCR-quantified patient samples in a proof-of-concept 
sensitivity and specificity study. This proof-of-principle paper-fluidic diagnostic, 
which can be completed within 80 minutes, selectively amplifies and detects NG 
  vii
in multiplex with NGIC. It has a clinically relevant limit of detection of 1000 NG cells 
per device. In urethral swab sample trials (N=20), the device approaches current 
gold standard NG diagnostic capabilities with 90% sensitivity and 100% specificity 
and vaginal swab sample trials (N=20) surpass the gold standard with 100% 
sensitivity and 100% specificity. 
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CHAPTER ONE: BACKGROUND AND INTRODUCTION 
  
Sexually transmitted infections (STIs) caused by Neisseria gonorrhoeae (NG) 
account for 106 million (Unemo, 2012) of all newly documented STI cases each 
year. In low resource settings, both in the United States and across the globe, 
many infected people remain untreated (Aledort 2006, Bourgeois 1998, WHO 
2007). Untreated gonorrhea infections can cause pelvic inflammatory disease, 
infertility, and ectopic pregnancy among women, and additional complications via 
neonatal transmission. NG infections can remain asymptomatic for years, reducing 
the number of patients seeking treatment while increasing the rate of transmission. 
NG infections also facilitate HIV transmission (Aledort 2006, Fleming 1999); people 
with NG infections are up to five times more likely to contract HIV (Wasserheit 
1992), and are three times more likely to transmit HIV to someone else (Fleming 
1999). Once diagnosed, this serious but treatable infection is often cured with a 
one-time dose of appropriate antibiotics. However, diagnosis through current 
state-of-the-art methods, such as swab sample culturing or PCR, require an 
equipped laboratory, trained staff, and several days or even weeks to complete. 
NG infections also have similar symptoms to other STIs, such as chlamydia and 
yeast infections, introducing additional confounding factors in NG diagnosis.  
 
Due to long turnaround times, patients often fail to return for diagnostic results and 
follow up treatment. As a result, the United States Centers for Disease Control and 
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Prevention (CDC) urges clinics to use point-of-care (POC) tests to ensure high-
risk patients receive treatment in the same visit (Papp 2014). Despite some 
progress in developing immunoassay based rapid diagnostic tests (RDTs) (Greer 
2008) and near-patient qPCR systems (Gaydos 2013), a specific, sensitive, and 
low-cost POC NG diagnostic is not yet available. While manufacturer reported 
sensitivities are as high as 98% for both urethral and vaginal swab samples (C 
Diagnostics 2006, Huppert 2010), clinical studies comparing multiple RDTs to 
qPCR have shown RDT sensitivities of only 70% for cervical swabs samples and 
as low as 54% for vaginal swab samples (Alary 2006). If available to clinicians, 
much more sensitive nucleic acid amplification tests (NAATs) are still 
recommended over immunological RDTs (CDC 2014, Papp 2014). 
 
In this work, we present an integrated system that bridges that gap between RDTs 
and laboratory-based NAATs. Our POC NG diagnostic device features integrated 
sample preparation, DNA amplification, and lateral flow detection. We had 
previously developed a portable and inexpensive paper-fluidic Human Papilloma 
Virus (HPV) diagnostic device composed of only of porous paper membranes and 
adhesive plastic (Rodriguez 2016). Here, we expand the platform to NG and 
enhance clinical reliability by incorporating an internal amplification control to 
differentiate between negative test results and invalid tests, a feature that will be 
inevitably required for regulatory approval of POC NAATs (FDA 2011, Lafleur 
2016, Papp 2014). In our NG diagnostic, cells in patient urethral and vaginal 
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samples are added to lysis buffer which is then washed through a porous 
polyethersulfone (PES) substrate to precipitate and concentrate sample DNA. 
Excess fluid is wicked away to a removable waste pad. NG DNA and internal 
control DNA (NGIC) are then amplified in a multiplexed isothermal, thermophilic 
helicase-dependent amplification (tHDA) reaction. Resulting molecular probe-
labeled amplicons flow to an integrated lateral flow strip (LFS) for visual detection.  
 
Our device yielded a reliable lower detection limit of 1000 genomic NG copies per 
reaction, which is sensitive enough to detect infections in clinical urethral swabs 
(Priest 2017) and vaginal swabs (Lowe 1976). We validated the device in a 
rigorous proof-of-concept study using discarded de-identified vaginal and urethral 
swabs (N=20 for each type) tested in three separate device trials. The results were 
only considered concordant with the qPCR reference standard when all three trials 
matched the qPCR result. In our study, our device had a NG sensitivity of 90.0% 
in urethral samples and 100% sensitivity in vaginal samples. Both sample types 
yielded a specificity of 100%, as no false positives were found in either urethral or 
vaginal swab sample device trials.  These promising results are an exciting proof-
of-principle demonstration for this POC NG NAAT platform. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
DNA Stocks, Cell Stocks 
NG strain NCTC 8375 (ATCC, Manassas, VA) was grown on chocolate agar in 5% 
CO2 at 37oC for 24-36 hours. Genomic NG DNA was harvested from cultured cells 
by incubating colonies in 10% sodium dodecyl sulfate. Cells were lysed in 5M 
guanidinum thiocyanate followed by phenol:chloroform DNA extraction and 
ethanol DNA precipitation (Dillard 2011) and was then quantified via Nanodrop. 
Nucleic acids isolated from 29 co-inhabitant venereal microbes (Table S2) were 
supplied from the Johns Hopkins Center for the Development of Point Of Care 
Tests for Sexually Transmitted Diseases at Johns Hopkins University (JHU).  
 
tHDA Assay 
Previously confirmed as PES compatible (Linnes 2016), our tHDA assay amplifies 
the highly conserved and single-copy porA pseudogene, which is specific to the 
NG genome (Unemo 2005). Primer sequences and assay components, originally 
designed by Biohelix Inc. (Quidel Corporation, San Diego, CA), are listed in Table 
1. 25µL in tube tHDA assays were performed for 30 minutes at 65°C via 
thermocycler to simulate optimal heating conditions. The internal amplification 
control, NGIC, is an engineered plasmid also provided by BioHelix Inc. that uses 
the same amplification primers as the target NG porA pseudogene but has a 
different molecular probe sequence, enabling differential detection. NG/NGIC 
tHDA multiplexing was optimized through titration and all subsequent tHDA 
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reactions in this work contain 10⁴ spiked in copies of NGIC plasmid. Successful 
amplification of NG and NGIC targets was confirmed via gel electrophoresis as 
well as detection of biotinylated amplicon-probe complexes on the LFS. Selective 
amplification of the NG porA pseudogene and NGIC was confirmed by sequencing 
gel extraction products. 
 
 
 
Acrylamide and Urea Gels 
Using gel electrophoresis, acrylamide (naturing) gels were used to analyze 
success of tHDA amplifications. 10% acrylamide gels poured in house. 2µL of 
tHDA reaction were added per well and gels were ran for 2hrs at 90V. Gels were 
then stained with SYBR green and imaged with a Versadoc Imager.  
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Denaturing urea gels to dismantle possible tHDA amplicon secondary structures. 
Denaturing gels were composed of 10% acrylamide, 40% urea, and additional 
polymerization solutions. To prevent ssDNA reannealing, Urea gels were ran at a 
constant temperature of 53°C. After casting, the urea gel was then preheated for 
30 minutes. Before gel loading, tHDA reactions were preconditioned for 
denaturization by heating 4µL of tHDA amplicon product with 4µl formamide (10%) 
with DNA loading dye and 2uL of glycerol (30%) at 95°C for 10 minutes. Reactions 
were then immediately placed on ice until loading into the gel. Maintaining the 
constant temperature, loaded gels were then ran at 40 watts for 45 minutes. 
Denaturing gels were then stained in SYBR Gold for 30 minutes before imaging 
with the Versadoc Imaging system.   
 
DNA Extraction from Acrylamide Gels 
To elucidate potential tHDA amplicon secondary structures, gel electrophoresis 
bands from NG and NGIC reactions were extracted from naturing acrylamide gels 
and denaturing urea acrylamide gels. Bands of interest were isolated from gels via 
scalpel excision. Isolated gel bands were crushed and introduced to an equal 
volume of 0.5M solution of ammonium acetate for 48 hours. DNA from the gel 
slurries was then extracted using a 0.22µm Millipore column and ethanol 
precipitation. The resultant amplicon isolates were reconstituted in 30µL of EB 
buffer and frozen at -20°C for later use. DNA structural properties and gel 
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extraction precision was additionally investigated by re-running gel extraction 
isolates via acrylamide and urea gels. 
 
Paper-fluidic Device Fabrication 
Device design and manufacture were developed by fellow graduate student, Justin 
Rosenbohm. The 30mm x 30mm cyclic olefin polymer (COP) reaction housing 
contained an 8.5mm circular hole as the center reaction chamber and was 
fabricated from 6 layers of COP (Zeon Chemicals, L.P., Louisville KY) with a 
GraphTec CE6000-40 cutting plotter (GraphTec Corporation, Irvine, CA). A 9.5mm 
diameter punch of a 0.22µm pore size PES membrane (EMD Millipore, Billerica, 
MA) was placed between the two bottom layers. The chip was bonded together 
with a heat press as previously described (Roy 2012). A waste pad laser-cut from 
Whatman #3 paper (Sigma Aldrich, St Louis, MO), and a commercial LFS with 
FITC, DIG, and streptavidin detection lines (#D005-05, Ustar Biotechnologies, 
Hangzhou China) were attached using 3mm thick self-adhesive plastic (Fellowes, 
Itasca, IL). Completed chips were stored in a sterile container until use. 
 
Integrated On-Chip Assay 
On-chip sample precipitation, washing, amplification, and LFS detection were 
modified from the protocol of Rodriguez et al. (Rodriguez 2016) and performed 
using spiked-in genomic NG DNA and reconstituted patient samples (Figure 1). 
Modifications to increase tHDA reaction stability during device heating, included 
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adding 15µL of mineral oil to the smaller reaction chamber cavity to increase heat 
transfer efficiency, as well as incubating the 25µL tHDA reaction on a heat block 
at 65°C for 45 minutes under a Styrofoam insulator. After adding 60µL of 
commercially supplied LFS running buffer, the detection and control lines on the 
attached LFS were read within 5 minutes. Acrylamide gel analysis of post-heated 
reactions additionally confirmed amplification. 
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Figure 1: Complete protocol for NG DNA precipitation, amplification, and 
detection within a low-cost paperfluidic device. Before device application, 5uL 
of patient sample is pipetted and lightly mixed with 95uL of lysis/precipitation 
buffer. The precipitant mix is then applied to the reaction chamber of the device 
via pipette (Figure 1A). To wash away sample and lysis buffer contaminants from 
the precipitated DNA, 200µL of 70% ethanol and 100µL of 95% ethanol are wicked 
through the PES to the waste pad (Figure 1B). After ethanol washing, the LFS is 
folded over (Figure 1C, in blue) and the waste pad is torn off and discarded (Figure 
1C, in green). After 10 minutes of dry time, 15µL of mineral oil (Figure 1D) is added 
to the smaller reaction chamber cavity and sealed with a tab. Next tHDA 
amplification mix (25µL) with spiked-in NGIC mix is then added to the larger cavity 
and sealed (Figure 1E). The LFS is folded back against the mineral oil side of the 
device before the device is heated for 45 minutes on standard heat block (Figure 
1F). The device sits underneath a Styrofoam insulation block with the reaction-side 
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facing down. Post heating, the tab sealing the tHDA amplification mix is removed, 
allowing the LFS inlet pad to access the reaction (Figure 1G, blue arrow). With 
60µL of LFS running buffer (Figure 1G, pipette tip), probe-labeled amplification 
products can flow down the LFS (Figure 1G, green arrow) and LFS-captured 
amplicons are interpreted via colorimetric read-out (Figure 1H). Figure 1I illustrates 
a NG-negative chip result (top image) and a NG-positive device result (bottom 
image).  
 
Lateral Flow Strip Detection 
Commercial LFS were purchased from U Star Biotechnologies (Hangzhou, China). 
NG probes were labeled with FITC while NGIC probes were tagged with DIG 
(Table 1) for detection on LFS via anti-DIG and anti-FITC stripes, respectively 
(Figure 2). LFS band intensities were imaged and quantified using ImageJ (NIH, 
Bethesda, MD). LFS bands were considered present or non-present via threshold-
based densitometry, where NG and NGIC band intensities were compared to the 
LFS background. 
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Figure 2: tHDA Small Molecular Probe Integration for Downstream Lateral 
Flow Detection. During tHDA amplification, internal control NGIC amplicons were 
labeled with a small molecular DIG probe and NG amplicons were labeled with a 
FITC probe. All amplicons are labeled with biotin, which was incorporated into the 
forward primer. During downstream lateral flow detection, gold-streptavidin 
nanoparticles attach to present biotin-labeled amplicons. The amplicons were 
trapped by anti-DIG and anti-FITC antibodies embedded in a nitrocellulose strip, 
and trapped gold nanoparticles convey a colorimetric signal (red bands). A biotin 
line acted as a positive flow control for gold-streptavidin particles. Present band 
combinations would then be used to convey differential diagnoses. 
 
Clinical Samples 
Previously de-identified, discard clinical samples from the Johns Hopkins 
University (JHU) bio-repository were used in the retrospective study containing a 
total of 40 vaginal and urethral patient swab samples with 10 NG positive and 10 
NG negative specimens of each sample type. These were collected and used in 
accordance with IRB protocols approved by Boston University and JHU. The 
diagnostic status of the samples was previously determined at JHU by using a 
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gold-standard benchtop assay, the MagNA-pure extraction and qPCR system. 
Vaginal swabs were qPCR tested with a duplicate swab from the same patient, 
while urethral swabs were initially tested and then reused in our study. Swabs were 
stored dry at -80°C until sample processing. Samples were processed (Figure 3) 
by thawing the swabs for 2 minutes at room temperature and then placing these 
into 150uL of sterile water in a 1.7mL tube. The tubes were vortexed for 30 
seconds, and the reconstituted sample was aliquoted for later device application 
and DNA extraction. Liquid aliquots were refrozen at -80°C. 
 
 
Figure 3: DNA Reconstitution from Frozen Patient Urethral and Vaginal 
Swabs. Dry, deidentified swabs stored long-term at -80°C were reconstituted for 
later clinical validation of devices and DNA extraction/quantification. Swabs were 
individually thawed, introduced to 150uL of sterile H20, and vortexed. Swabs were 
then discarded and 18uL of fluid was aliquoted into PCR tubes for later use. The 
remainder of fluid was also measured for volume and collected for DNA extraction. 
All aliquots were refrozen to -80°C prior to use.  
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qPCR Confirmation of Human and NG DNA in Clinical Samples 
Isolated DNA from reconstituted patient samples was extracted via a Qiagen Blood 
and Tissue kit (Qiagen Corporation, Hilden, Germany). Following DNA extraction, 
patient samples were tested for DNA integrity via the detection of the human 
RNAseP housekeeping gene and NG genomic loads were quantified via SureStart 
Taq polymerase (Agilent, Santa Clara, CA) qPCR per manufacturer’s instructions.  
Reactions were quantified using the QuantStudio5 Real-Time PCR system 
(Thermo Scientific, Waltham, MA). Primers and probes for the RNAseP and NG 
assays were purchased from Integrated DNA Technologies (Coralville, IA), as 
described in Table 1. Samples were heated to 95⁰C for 10 minutes followed by 45 
cycles of 95⁰C for 15 seconds, 60⁰C for 30 seconds, and 72⁰C for 15 seconds. 
 
Statistical Analyses 
The limit of detection was determined as the lowest DNA concentration that yielded 
100% NG amplification rates detectable by LFS in all three replicate trials. Chips 
and benchtop reactions with neither NG nor NGIC LFS lines were discarded from 
analysis due to failed tHDA, and reactions with no LFS lines at all were discarded 
for faulty flow conditions. Chips with weakly red NGIC or flow control lines but very 
strong NG lines were included, as positive NG detection was still observed 
(Gervais 2009).   
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Using the positive and negative patient samples as a comparative test set, we 
determined the paper-fludic device’s preliminary diagnostic sensitivity and 
specificity. Multiple devices per patient sample were used to assess device-to-
device variability. Results of the three device trials per sample were binned 
together and we required that all three device results be concordant with the JHU 
qPCR reference standard in order to be considered a true positive or true negative 
result. We calculated positive predictive value, negative predictive value, 
sensitivity, and specificity of our NG assay device. For all calculations, we 
additionally determined 95% confidence intervals.  
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CHAPTER THREE: NG/NGIC MULTIPLEX tHDA ASSAY DEVELOPMENT 
 
To detect NG infections in low-resource conditions, expensive DNA amplification 
equipment such as thermocyclers can be circumvented through the use of 
isothermal DNA amplification strategies. Instead of relying on heat for DNA 
denaturization, tHDA separates DNA isothermally via the DNA unwinding enzyme, 
helicase. 
 
In our tHDA strategy, we specifically target NG infections by amplifying an 81bp 
region of the NG-specific porA pseudogene (Unemo 2005). In the pre-designed 
NG/NGIC tHDA assay supplied by Biohelix, target amplicons and a spiked-in 
competitive internal control plasmid (NGIC) are amplified and labeled in multiplex 
for downstream detection. Positive NGIC amplification and detection allow users 
to confirm proper amplification conditions by differentiating between negative and 
failed device runs. As a competitive assay, both NG and NGIC targets compete for 
amplification reagents—the tHDA primers anneal to both the porA pseudogene 
and the spiked-in engineered plasmid. Specific FITC and DIG-labeled probes 
anneal to NG and NGIC amplicons and the probe-labeled amplicons are then 
detected via an antibody-based colorimetric reaction on a lateral flow strip. To 
validate the efficacy of tHDA for use in our diagnostic platform, NG and NGIC 
amplicons were characterized for appropriate product size, multiplexing 
capabilities, sequence, assay selectivity against co-inhabitant venereal 
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populations, and overall assay limit of NG detection. The assay’s limit of detection 
was then compared to projected bacterial loads in clinical swab samples. If the 
assay limit of detection was lower than clinical sample bacterial loads, the assay 
was considered fully optimized to begin in-device compatibility studies.  
 
In our multiplex tHDA assay characterization, the NGIC titration experiment gave 
the best NG and NGIC signals at 10⁴ NGIC copies per reaction. When the multiplex 
assay was tested against 29 co-inhabitant microflora, it maintained amplification 
selectivity for only NG-positive DNA. In the limit of detection experiment, the 
multiplex detected NG 100% of the time in reactions with 500 NG copies per 
reaction or more, which is well under expected clinical swab bacterial loads. 
However, both NG and NGIC tHDA amplicons yielded a strange “double band” 
phenomena. Using a gel electrophoretic strand separation protocol, we found 
unexpected secondary DNA structure in the produced amplicons. 
 
tHDA Multiplex Verification and Titration  
In the tHDA mix, the target and the internal control amplify with the same primers 
and reaction reagents in a competitive manner. To make sure the competitive 
multiplex assay can sensitively detect the NG target while still robustly amplifying 
the internal control (NGIC), titrating NGIC against the target is essential. Therefore, 
at high concentrations of either target or NGIC DNA, the production of one 
amplicon outcompetes the amplification of other targets. To find the appropriate 
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level of spiked-in NGIC for future reactions, different NGIC plasmid concentrations 
were titrated against various concentrations of isolated NG DNA. The lowest 
concentration of NGIC that allowed for robust NGIC amplification as well as strong 
NG amplification at low NG concentrations was chosen for future experiments. 
Figure 4 is a preliminary titration test showing successful multiplexing between NG 
and its internal control at varying NG concentrations as well as NG out-competition 
of NGIC amplification at high NG concentrations. Ultimately 10⁴ copies of NGIC 
plasmid per reaction was chosen as the spiked-in plasmid concentration for later 
multiplex characterization assays.   
 
 
 
Figure 4: Titration of NGIC plasmid against various concentrations of 
isolated NG DNA. To find the appropriate level of spiked-in NGIC for future 
reactions, different NGIC plasmid concentrations were titrated against various 
concentrations of isolated NG DNA. The lowest concentration of NGIC that 
allowed for robust NGIC amplification as well as strong NG amplification at low 
NG concentrations was chosen for future experiments. 
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Assay Selectivity against Co-Inhabitant Microflora  
To confirm selectivity for the NG-specific porA pseudogene, we tested our 
multiplexed tHDA assay against a range of potential confounding microbes. By 
testing 29 bacterial and viral species that commonly inhabit human genitalia 
(Brotman 2011, FDA 2011, Price 2010) with the NG-only and NG-NGIC multiplex 
assays, we screened for non-specific amplification even with high DNA genomic 
loads under optimal heating conditions. In our multiplexed benchtop assay, we 
found no cross-species amplification within any of the tested bacterial and viral 
genomes, as summarized in Table 2.  
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Assessing Assay Selectivity through Sequencing of tHDA Multiplex Products 
To further verify the selective amplification of NG’s porA pseudogene and the 
spiked-in NGIC plasmid, post-tHDA reaction product of NG and NGIC was 
extracted from 10% acrylamide gels and sequenced using standard plasmid vector 
cloning procedures. Using APE software, the resulting isolate sequences were 
compared to the known NG and NGIC sequences. Both targets were present in 
their respective band isolates (Figure 5).  
 
 
 
Figure 5: Sequencing of Isolated NG and NGIC tHDA Amplicons. To confirm 
multiplex assay selectivity, amplicons were isolated from acrylamide gels, cloned, 
and sequenced. For each amplicon, the projected sequences are given above 
the APE software screenshots. Grey regions in the APE sequence screenshots 
highlight the sequenced amplicons.  
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NG/NGIC tHDA Assay Limits of Detection 
To develop a robust multiplex assay that would signal appropriate amplification 
conditions while still detecting low concentrations of NG in patient samples, we 
determined if the assay’s limit of detection was below projected NG loads in clinical 
swab samples. The lowest NG concentration that amplified in 100% of trials was 
considered the multiplex assay’s limit of detection. Using a NGIC concentration of 
104 copies per reaction, the multiplex assay reliably detected 500 genomic copies 
per reaction across 9 individual trials. The multiplex assay was capable of 
detecting as few as 10 genomic copies per reaction (Figure 7). The assay’s limit 
of detection was found to be well below expected NG cell loads in patient urethral 
swabs (approximately 3.7*10⁶ NG cells per swab (Priest 2017)).  With an assay 
that sensitively detects NG, the assay was approved for integration into the paper 
fluidic device.  
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Figure 6: Limit of NG DNA detection with the NG/NGIC tHDA multiplex assay 
in optimal heating conditions (thermocycler). To determine the multiplex tHDA 
assay’s limit of NG detection, serially diluted genomic NG DNA was amplified in a 
thermocycler and analyzed via gel electrophoresis (top) and LFS threshold 
densitometry (bottom). Representative reactions for each concentration are 
illustrated here. The lowest concentration of DNA that yielded 100% amplification 
success in all trials (N=9) is considered the assay’s limit of NG detection (red 
asterisk). 
 
 
Additional NG/NGIC tHDA Multiplex Questions 
One notable and consistent problem with the NG/NGIC assay was that NGIC 
would show as positive in lateral flow strips in NG-only amplifications (Figure 6, 
second strip). We speculated that there is some non-specific binding between the 
NGIC probe and the NG amplicons. While false NGIC positive reactions aren’t 
optimal, we retained it as the internal control as it never came up as positive in 
negative DNA controls, so no false-positive amplifications were observed. For 
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future studies, we may design a new internal competitive control with a more non-
homologous probe, or move to a non-competitive spiked-in plasmid target. 
 
While the NG/NGIC tHDA multiplex assay yielded target selectivity (Table 2) and 
its amplicons bore the appropriate sequences (Figure 5), a strange double banding 
pattern was found in all acrylamide gel electrophoresis experiments (Figures 4 and 
6). Secondary structures was expected, since most gels exhibited high-weighted 
patterns at the gel loading sites (Figure 7a, “Naturing Gel” extract “700N”). To 
further understand these patterns, NG amplicons from an NG-only tHDA 
amplification were ran on a denaturing gel. The denaturing gel separated 
amplicons into ssDNA and removed any corresponding secondary DNA 
structures. In these initial denaturing studies (Figure 7A, “Denaturing Gel”), we 
found a new and larger amplicon product (~115bps) that wasn’t previously 
observed in the acrylamide naturing gels.  
 
To see which of the two NG amplicon bands from acrylamide gels corresponded 
to the high-running band found in the urea gel, NG amplicons were extracted from 
both naturing acrylamide gels and from denaturing urea acrylamide gels (Figure 
7A). Extracts were then re-ran on both naturing and denaturing gels to see how 
the secondary structures of the bands changed from one gel type to another 
(Figure 7B). 
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Figure 7: Secondary DNA Structure Analysis of the tHDA NG Amplicon. 
Amplicons from the tHDA assay consistently had a high-weight smearing pattern 
as well as “double band” pattering, suggesting secondary DNA structures. Figure 
7A: Observed band types in acrylamide naturing gels and urea denaturing gels 
that were extracted for later structural analysis (red boxes). Figure 7B:  Re-
application of extracted bands to naturing gels and denaturing gels. Key: N = 
originated from naturing gel, D = originated from denaturing gel, T= top band, B = 
bottom band. To reduce variables, all reactions used in structural experiments 
were NG-only reactions, with no NGIC DNA or NGIC probe. 
 
Extractions from the naturing and denaturing gels resumed their locations when 
re-ran on their corresponding gel types. However, some extractions from the 
naturing gels ran oddly when ran in denaturing conditions. For example, the NG 
band extracted from the “top” NG band in the acrylamide gel ran at the amplicon’s 
target size in the denaturing gel (sample “81N-Bottom”).  Additionally, the NG 
extraction that ran at a lower product size on the naturing gel (sample “81N-
Bottom”) ran at a higher product size in the denaturing gel. Here, sample 81N-
Bottom ran at an identical height to the higher product size (115bps) initially found 
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in early denaturing experiments (Figure 7A), suggesting that this longer ssDNA 
fragment exhibits secondary structures in the naturing gel, as it runs to a lower 
product size than the other NG ssDNA. 
 
DNA extracted from a NG tHDA reaction enriched via lateral flow strip (Figure 
7B, “Denaturing Gel”) suggest that both the high-weight and low-weight sizes are 
involved in lateral flow strip binding and molecular probe integration, as both 
sizes are present in similar amounts. With two separate ssDNA band sizes, the 
additional high-weight band may be a tHDA-based amplification artifact, NGIC 
plasmid contamination, or perhaps some off-target amplification. We attempted 
to isolate and sequence the high-weight ssDNA band to elucidate the 
mechanisms behind the secondary structures, but cloning attempts were 
unsuccessful.
  
26
CHAPTER FOUR: NG/NGIC tHDA ASSAY INTEGRATION INTO THE PAPER 
FLUIDIC DEVICE 
 
Once the assay was characterized, we were ready to integrate it into the device. 
Designed for tHDA-use by lab-mate Justin Rosenbohm, the paper fluidic device 
condenses DNA from patient samples via chemical precipitation. The precipitated 
DNA can then be amplified with tHDA and constant heat before the reaction is 
flowed to a lateral flow strip for result interpretation. However, moving the multiplex 
assay directly to the device resulted in a substantial loss in assay sensitivity—
amplification was only seen in devices with 10⁵-10⁶ copies of NG DNA. In the 
device, NG DNA capture now relied on precipitation, washing, and appropriate 
paper-fluidic wicking, while heating was reliant on conductance from a heat block 
instead of a highly regulated thermocycler. To improve assay performance, the 
assay and device needed to be optimized for one another. 
 
In our optimization studies, we found that leftover salt from the precipitation step 
negatively affected tHDA amplification, the heating time needed to be extended, 
and reaction heating required additional stabilization via mineral oil. Once the 
assay and device were better optimized for one another, the device limit of 
detection was only two times greater than the optimal thermocycler-based 
amplifications. With such a successful transfer of assay sensitivity to device 
sensitivity, the device was ready for proof-of-concept clinical validation studies.  
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NG/NGIC tHDA Assay Salt Adjustment  
According to the tHDA manufacturer, tHDA reactions are sensitive to salt 
concentrations.  Our lysis-DNA precipitation buffer contains 300mM of NaCl, so 
we checked if there was residual NaCl on the PES paper substrate. To do so, we 
changed our standard tHDA reaction mix (35mM NaCl) to a “salt-less” version 
(0mM). Since “salt-less” tHDA doesn’t amplify in optimal conditions, we found that 
the residual salt on the PES rescues tHDA amplification (Figure 8A). To 
accommodate for residual salt in the device’s reaction chamber, we adjusted our 
tHDA reaction mix NaCl concentration from 35mM to 20mM, which improved in-
chip amplification. 
 
Device Run-Time Adjustment 
Since lengthening amplification time increases the amplification signal in any DNA 
amplification assay, we increased tHDA amplification time from 30 minutes to 45 
minutes. Lengthening the assay produced a respectable increase in NG signal, as 
2 out of 3 reactions amplified in the 45 minute reactions when no reactions 
amplified in the 30 minute reactions (Figure 8B). While our goal was to generate a 
device that could deliver a diagnostic answer in under an hour, we found that 
adding 15 minutes to device run-time significantly improved device amplification 
success.  
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Reaction Stabilization via Mineral Oil 
After salt and run-time adjustments, the device still had substantially worse 
amplification success than optimal thermocycler-heated reactions (Figure 6). Air 
pressure from heating often popped off the device lid, which led to reaction 
leakage. Reaction evaporation and condensation patterns were also observed. To 
prevent evaporation in thermocycler tHDA reactions, mineral oil is added to the top 
of reactions. To simulate this effect, we added 15uL of mineral oil to the opposite 
side of the PES chamber as an attempt to improve reaction stability (Figure 8C). 
In the five devices tested without mineral oil, there was digital amplification with 
inconsistent amplification efficiencies, and a higher prevalence of primer dimers. 
In the five devices supplemented with mineral oil, primer dimers occurred less 
while NG amplicon intensity and consistency improved dramatically. With high and 
consistent amplification at a point that was once previously unattainable (10⁴ NG 
copies per reaction), the optimized device was ready for limit of NG detection 
testing. 
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Figure 8: NG/NGIC tHDA Assay Integration into the Paper Fluidic Device.  
To improve multiplex tHDA amplification within the device, several device and 
assay parameters were optimized. Figure 8A: NaCl rescue of 0mM NaCl tHDA 
reactions. “In tube” reactions were performed using an optimal heating source 
(thermocycler). NTC = no template control. “In Device” reactions were amplified 
within devices treated with the DNA precipitation protocol. Figure 8B: Device run-
time extension. C# = Device replicate. CN = Device No Template Control. Figure 
8C: tHDA reaction stabilization with mineral oil. ITC = In tube (thermocycler) 
control. All assays contain 10⁴ NG copies per reaction, with 10⁴ copies of spiked-
in NGIC plasmid.  
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Limit of NG Detection within the Device  
To test the integration efficiency between the assay and the device, a limit of 
detection study was performed. Again, the lowest NG concentration that amplified 
in 100% of device trials was considered the device’s limit of NG detection.  When 
transferred to the device, the limit of NG detection was slightly weakened to 1000 
genomic NG copies, with digital amplification down to 100 copies per device 
(Figure 9). Despite this, the device detection limit was still well above expected 
patient sample bacterial loads (Priest 2017, Lowe 1976).  
 
Figure 9: Limit of NG DNA detection with the NG/NGIC tHDA multiplex assay 
in the paper fluidic device. To determine the paper fluidic device’s limit of NG 
detection, serially diluted genomic NG DNA was amplified under the device 
protocol (Figure 1). Reactions extracted from the devices were analyzed via gel 
electrophoresis (top) and LFS threshold densitometry (bottom). Representative 
device reactions for each concentration are illustrated here. The lowest 
concentration of DNA that yielded 100% amplification success in all trials (N=6) is 
considered the limit of NG detection for the device (red asterisk). 
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Comparing Limit of NG Detection between Optimal Heating Conditions and the 
Device  
In perfect assay-to-device implementation, the device would be able to amplify 
DNA as efficiently as a thermocycler. Comparing the device’s limit of detection to 
the thermocycler’s limit of detection, the device was only two times weaker at NG 
detection than the specialized laboratory equipment (Table 3). Slightly poorer 
device-based detection may have been caused by partial sample recovery during 
DNA precipitation, or by tHDA inhibition due to incomplete rinsing of DNA lysis and 
precipitation buffer, or a reduction in reaction heating efficiency. However, the 
device’s limit of NG detection continued to be well below the range of expected 
bacterial loads in clinical swab samples, so we were prepared to clinically validate 
the device against discarded patient samples. 
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CHAPTER FIVE: CLINICAL VALIDATION OF DEVICE WITH DISCARDED 
PATIENT URETHRAL AND VAGINAL SWAB SAMPLES 
 
Once the device was optimized, we clinically validated it against previously 
diagnosed urethral and vaginal swabs. In this retrospective study, we were able to 
determine NG bacterial loads of individual swabs, test our device’s diagnostic 
reliability by running multiple trials, and determine proof-of-concept sensitivity and 
specificity values for detecting NG infections.  
 
qPCR Quantification of Human and NG Bacterial Loads in Clinical Samples 
Having demonstrated assay selectivity and a clinically relevant device limit of 
detection for NG in our integrated device, we next determined the expected NG 
bacterial load in clinical urethral and vaginal swab samples using qPCR (Table 4).  
No NG DNA was detected in the 20 NG-negative swabs. In the NG-positive patient 
samples, qPCR quantification of patient sample DNA extracts showed an average 
of 6.59*10⁴ porA pseudogene copies per swab across the NG-positive urethral 
swab isolates and an estimated average of 2.86*10⁶ copies per swab over the NG-
positive vaginal swab isolates. Using these qPCR values, the approximate average 
NG DNA concentrations input into the device were 2.53*10³ organisms per urethral 
swab and 1.81*10⁵ organisms per vaginal swab. 
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Clinical Validation of Device 
To evaluate our device’s performance in a clinical context, the patient sample 
isolates were each tested in three separate device trials. Overall conditions for 
successful amplification were present in 88% of the vaginal samples and in 92% 
of the urethral samples (Table 4). Device trials were only considered correlative 
with the JHU standard if all three device trials concurred with the reference 
standard. Our paper-fluidic device repeatedly detected NG DNA from reconstituted 
swabs across all three device trials in 9 out of 10 NG-positive urethral swab 
samples and in 10 out of 10 NG-positive vaginal swabs (Table 4). Additionally, we 
saw no false positive NG detection in replicate detection of the 10 negative vaginal 
or the 10 negative urethral swab trials. Using these values, we calculated 
sensitivity, specificity, positive predictive value, and negative predictive value for 
patient samples in the device based assay (Table 5). Here, we saw a sensitivity of 
90% and specificities of 100% in the urethral swabs, as well as 100% sensitivity 
and 100% specificity in vaginal swabs.  
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CHAPTER SIX: DISCUSSION 
 
Using a previously developed NG/NGIC tHDA assay from BioHelix, we optimized 
the assay for multiplexing and then successfully integrated the assay into a low-
cost paper-fluidic device for sensitive and specific detection of NG DNA from 
urethral and vaginal samples. Overall device run-time approaches suitability for 
the clinical point of care at 80 minutes turnaround time from sample-to-result.  
 
One notable and consistent problem with the NG/NGIC assay was that NGIC 
would show as positive in lateral flow strips in NG-only amplifications. We 
speculated that there is some non-specific binding between the NGIC probe and 
the NG amplicons. While false NGIC positive reactions aren’t optimal, we retained 
it as the internal control as it never came up as positive in negative DNA controls, 
so no false-positive amplifications were observed. For future studies, we may 
design a new internal competitive control with a more non-homologous probe, or 
move to a non-competitive spiked-in plasmid target. 
 
While the NG/NGIC tHDA multiplex assay yielded target selectivity, a strange 
double banding pattern was found in all acrylamide gel electrophoresis 
experiments. To further understand these DNA secondary structure patterns, NG 
amplicons from an NG-only tHDA amplification were ran on a denaturing gel. In 
these initial denaturing studies, we found a new and larger amplicon product that 
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wasn’t previously observed in the acrylamide gels. With two separate ssDNA band 
sizes, the additional high-weight band may be a tHDA-based amplification artifact, 
NGIC plasmid contamination, or perhaps some off-target amplification. We 
attempted to isolate and sequence the high-weight ssDNA band to elucidate the 
mechanisms behind the secondary structures, but cloning attempts were 
unsuccessful. 
 
In the tHDA limit of detection studies, there is a slight reduction in the device 
detection limit (1000 genomic copies per reaction) as compared to the benchtop 
results (500 genomic copies per reaction). Slightly poorer device-based detection 
may have been caused by partial sample recovery during DNA precipitation, or by 
tHDA inhibition due to incomplete rinsing of DNA lysis and precipitation buffer, or 
a reduction in reaction heating efficiency.  
 
While our device can reliably detect 1000 NG cells, some bacterial load qPCR 
estimates fell below this projected limit of detection (e.g., NG positive urethral 
samples #2, 3, 6, and 9 (Table 4)).  We hypothesize that the extraction efficiency 
of the membrane-based precipitation used in the device may have actually been 
better than the silica-based commercial kit used to prepare our qPCR swab 
samples. Membrane-based precipitation has been shown to be effective at even 
low concentrations of DNA (Linnes 2014), while previous reports have shown 
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significant gDNA losses from silica-based kits at DNA concentrations below 10⁴ 
CFU/mL (Kulinski 2009). 
 
We additionally saw a reduced bacterial load in our qPCR measurements when 
comparing our urethral swab NG bacterial load quantifications to a previous study 
(Priest 2017). While extraction efficiency may play a role in this reduction, the 
urethral swabs we received had already been used for initial diagnostic testing and 
some material was certainly removed during this process. To our knowledge at the 
time of this study, NG bacterial loads in vaginal swab samples had not been 
previously reported and therefore were not available for comparison. 
 
We performed critical experiments to ensure clinical device reliability by evaluating 
multiple device trials in our limit of detection as well as patient sample validation 
studies. In limit of detection experiments with pre-isolated NG DNA, the frequency 
of device success was 96%. Only 2 out of 50 chips tested failed to amplify either 
NG or NGIC targets. In patient sample trials, overall conditions for successful 
amplification were present in 88% of the vaginal samples and in 92% of the urethral 
samples (Table 4). While amplification success in both NG-positive urethral and 
vaginal swabs were 100%, conditions for successful NGIC amplification in 
negative swab samples occurred in only 70% of the vaginal samples and in 83% 
of the urethral samples. Inclusion of NGIC enabled this important differentiation 
between sample negative, and failed amplification conditions. When comparing to 
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the pre-isolated NG DNA trials, the lowered success of NGIC amplification in NG-
negative swab device trials suggests that both urethral and vaginal patient sample 
matrices introduce some inhibition to amplification. We anticipate that patient 
sample matrices lead to a drop in NGIC amplification from factors not found in 
contrived samples. To improve the device success rate in NG negative patient 
samples, NGIC amplification will require further optimization, such as adjusting 
assay salt balance and ensuring complete washing for removal of the patient 
sample matrices. 
 
For rapid NG NAAT diagnostic device development, the Food and Drug 
Administration (FDA) suggests devices have 95% sensitivity and specificity (FDA 
2011). In urethral samples, our small trial approaches these diagnostic limits with 
90% sensitivity and 100% specificity to NG infections. In the vaginal samples, our 
device fits well within the FDA specifications, with 100% specificity and 100% 
sensitivity. Replicate trials illustrated diagnostic disparity in only 1 out of the 40 
patient samples, likely due to NG concentrations near the assay limit of detection. 
These results suggest that future larger clinical validation studies can be performed 
with one device per sample for both vaginal and urethral sample types. To further 
investigate the limit of NG detection, sensitivity, and specificity, future trials will 
include blinded samples of a larger number of patient swabs as well as 
prospectively collected swabs from patients diagnosed with both asymptomatic 
and symptomatic NG infections. 
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Further development of this platform will focus on reducing the turnaround time 
from 80 minutes to under 60 minutes. Presently, patient sample processing and 
reaction chamber drying require 30 minutes,  amplification requires 45 minutes, 
and LFS interpretation another 5 minutes. To reduce device run time and 
amplification success, we are optimizing tHDA efficiency. This diagnostic platform 
could overcome many barriers currently faced in limited-resource settings and 
increase access to accurate NG diagnoses to those most in need.  
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